View Older Stories View More Recent Stories

Jul 21, 2016 09:04AM Amgen (AMGN), Allergan (AGN) Announce Results from ABP 980 Phase 3 in HER2+ Breast Cancer; Superiority Not Ruled Out
Jul 21, 2016 09:00AM Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Jul 20, 2016 08:29PM Amgen Announces Settlement Of Securities Litigation
Jul 14, 2016 06:06AM Amgen (AMGN), Daiichi Sankyo Enter Biosimilars Commercialization Agreement in Japan
Jul 13, 2016 09:00PM Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
Jul 12, 2016 07:32AM Amgen (AMGN) Announces Meeting with U.S. FDA to Discuss ABP 501 BLA
Jul 12, 2016 07:30AM Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab
Jul 11, 2016 09:03AM Amgen's (AMGN) Repatha Pushtronex System Receives FDA Approval
Jul 11, 2016 09:00AM FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor
Jul 5, 2016 06:06AM Amgen (AMGN) Receives EC Approval for Extended Kyprolis Indication in Relapsed Multiple Myeloma
Jul 4, 2016 01:00AM European Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Jun 22, 2016 06:00PM Amgen Sponsors QB3@953 Incubator For Life Science Startups
Jun 17, 2016 04:00PM Amgen Appoints Esteban Santos Executive Vice President, Operations
Jun 13, 2016 04:01PM Amgen (AMGN) Announces FDA Advisory Committee Meeting for ABP 501
Jun 13, 2016 04:00PM Amgen Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab
Jun 10, 2016 04:02PM Amgen (AMGN) Announces Results from Post-Hoc Analysis of Pivotal Phase 3 ASPIRE Study
Jun 10, 2016 04:00PM New Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression
Jun 10, 2016 02:30AM BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
Jun 8, 2016 04:32PM Amgen (AMGN) Announces Erenumab Phase 2 Met Primary Endpoint in Chronic Migraine Prevention
Jun 8, 2016 04:30PM Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine
Jun 7, 2016 09:00AM New National Survey Sheds Light On How To Better Engage Students In Science Education
Jun 6, 2016 04:02PM Amgen (AMGN) Announces Presentation of Kyprolis Phase 3 Data in Relapsing Multiple Myeloma; Improved PFS, ORR Noted
Jun 6, 2016 04:00PM New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis® (Carfilzomib)-Based Regimen
Jun 3, 2016 04:15PM Amgen Announces Launch Of KYPROLIS® (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers
Jun 3, 2016 04:00PM Amgen To Present At The Goldman Sachs 37th Annual Global Healthcare Conference
May 27, 2016 07:30AM Amgen (AMGN) Announces Receipt of Positive EMA CHMP Opinion on Kyprolis as Relapsed Multiple Myeloma Treatment
May 27, 2016 07:21AM Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma
May 26, 2016 04:01PM Amgen (AMGN) Kyprolis Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript
May 26, 2016 04:00PM Kyprolis® (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics"
May 19, 2016 06:02PM Amgen Announces Voting Results of Annual Meeting of Stockholders
May 19, 2016 04:36PM Amgen (AMGN) Will Present BLINCYTO, Kyprolis, Aranesp, and Nplate Data at EHA 2016
May 19, 2016 04:34PM Amgen Highlights Data To Be Presented At 21st Congress Of The European Hematology Association
May 18, 2016 05:10PM Amgen (AMGN) Says Data to be Presented at ASCO Shows Insights Into Treatment Options For Patients
May 18, 2016 05:05PM Amgen Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients
May 17, 2016 04:00PM Amgen's Breakaway from Cancer® Public Service Announcement Delivers Message That Education, Resources And Hope Are Essential In The Fight Against Cancer
May 11, 2016 06:57AM Amgen (AMGN) Teams with NFL Legend Joe Montana for New 'Breakaway from Heart Disease' Campaign
May 11, 2016 06:45AM Hall of Fame Quarterback Joe Montana and Amgen Team Up to Launch Breakaway from Heart Disease™ to Make Heart Health a Priority
May 9, 2016 09:15AM Platelet BioGenesis Wins Amgen Golden Ticket For LabCentral
May 6, 2016 04:00PM Amgen To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
May 3, 2016 04:22PM Amgen's (AMGN) BLINCYTO sBLA Granted FDA Priority Review as Treatment of Certain ALL
May 3, 2016 04:21PM FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For BLINCYTO® (Blinatumomab)
Apr 28, 2016 04:01PM Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90
Apr 25, 2016 05:30PM Amgen Announces Webcast Of 2016 First Quarter Financial Results
Apr 25, 2016 09:00AM Amgen To Participate In The 2016 World Medical Innovation Forum™ On Cancer
Apr 19, 2016 04:01PM Amgen (AMGN) Says Study in The Lancet Shows Nplate Significantly Increases Durable Platelet Response
Apr 19, 2016 04:00PM Nplate® (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia
Apr 3, 2016 12:17PM Amgen (AMGN) Announces Publication of Positive Repatha Phase 3 GAUSS-3 Data
Apr 3, 2016 09:05AM Positive Efficacy And Tolerability Study Of Repatha® (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association"
Apr 1, 2016 04:01PM Amgen (AMGN), UCB Phase 3 Data Comparing Romosozumab With Teriparatide Presented at ENDO
Apr 1, 2016 04:00PM Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide
View More Recent Stories View Older Stories